US2022041681A1PendingUtilityA1

Glucagon and glp-1 co-agonists for the treatment of obesity

60
Assignee: MEDIMMUNE LTDPriority: Mar 10, 2016Filed: Aug 26, 2021Published: Feb 10, 2022
Est. expiryMar 10, 2036(~9.6 yrs left)· nominal 20-yr term from priority
Inventors:Maria BednarekLutz JermutusPhilip AmberyMarcella Petrone
A61P 3/10A61P 3/04A61K 38/26A61K 38/00A61P 1/16C07K 14/605A61K 9/0019
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonist peptides.

Claims

exact text as granted — not AI-modified
1 - 69 . (canceled) 
     
     
         70 . A method of reducing body fat comprising administering to a human subject in need thereof 50-600 μg of a peptide comprising the amino acid sequence of SEQ ID NO:19. 
     
     
         71 . A method of treating obesity comprising administering to a human subject in need thereof 50-600 μg of a peptide comprising the amino acid sequence of SEQ ID NO:19. 
     
     
         72 . (canceled) 
     
     
         73 . A method of managing weight comprising administering to a human subject in need thereof 50-600 μg of a peptide comprising the amino acid sequence of SEQ ID NO:19. 
     
     
         74 - 177 . (canceled)

Join the waitlist — get patent alerts

Track US2022041681A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.